Announcing Positive Results of Saturn-2 Phase 3 Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis
Revolutionizing treatment for patients in need
Scroll To Discover
About
We’re committed to delivering boundless therapeutic ingenuity
Tarsus Pharmaceuticals, Inc. is a biopharmaceutical company that embodies the values of commitment, empowerment, and teamwork. We aim to bring novel therapeutics to patients across a range of diseases with limited treatment options.
Pipeline
Novel therapies, beginning with the eye
For the millions of patients living with Demodex blepharitis, an FDA-approved treatment is on the horizon.
News & Media
Here is the latest from Tarsus
08/11/2022
Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements
08/05/2022
Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease
05/27/2022
Tarsus to Present at the Jefferies 2022 Healthcare Conference
15440 Laguna Canyon Road, Ste 160
Irvine, CA 92618
2022 Tarsus Pharmaceuticals, Inc. All rights reserved.
TARSUS and the associated logo are trademarks of Tarsus Pharmaceuticals, Inc.
Contact Tarsus
Please reach out to us using the form below."*" indicates required fields